ABT vs CUBE · P/E 25, rev $44.33B vs P/E 25, rev $1.07B
Abbott Laboratories (ABT) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the ABT and CUBE stock pages for the full models.
Not investment advice.